drugset / Trial / NCT01789281

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

NCT01789281

Phase 4 Completed 34 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

Study to allow access to everolimus for patients who are on everolimus treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator

Timeline

Start
2013-05-14
Primary completion
2020-08-28
Completion
2020-08-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule Oral
Background Octreotide Peptide Intramuscular

Indications